JIN MEDICAL INTERNATIONAL LT (ZJYL)
KYG5140V1124 - Common Stock
We assign a fundamental rating of 4 out of 10 to ZJYL. ZJYL was compared to 187 industry peers in the Health Care Equipment & Supplies industry. ZJYL scores excellent on profitability, but there are some minor concerns on its financial health. ZJYL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ZJYL was profitable.
In the past year ZJYL had a positive cash flow from operations.
Each year in the past 5 years ZJYL has been profitable.
Of the past 5 years ZJYL 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of ZJYL (7.06%) is better than 88.24% of its industry peers.
ZJYL has a better Return On Equity (11.07%) than 85.56% of its industry peers.
The Return On Invested Capital of ZJYL (5.10%) is better than 78.07% of its industry peers.
ZJYL had an Average Return On Invested Capital over the past 3 years of 11.31%. This is above the industry average of 8.19%.
The last Return On Invested Capital (5.10%) for ZJYL is well below the 3 year average (11.31%), which needs to be investigated, but indicates that ZJYL had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.06% | ||
| ROE | 11.07% | ||
| ROIC | 5.1% |
ROA(3y)11.23%
ROA(5y)12.44%
ROE(3y)16.18%
ROE(5y)20.61%
ROIC(3y)11.31%
ROIC(5y)14.68%
1.3 Margins
With an excellent Profit Margin value of 14.44%, ZJYL belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
In the last couple of years the Profit Margin of ZJYL has declined.
ZJYL has a Operating Margin of 11.55%. This is in the better half of the industry: ZJYL outperforms 79.68% of its industry peers.
ZJYL's Operating Margin has declined in the last couple of years.
ZJYL's Gross Margin of 34.73% is on the low side compared to the rest of the industry. ZJYL is outperformed by 70.59% of its industry peers.
ZJYL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.55% | ||
| PM (TTM) | 14.44% | ||
| GM | 34.73% |
OM growth 3Y-0.18%
OM growth 5Y-6.48%
PM growth 3Y2.15%
PM growth 5Y-3.78%
GM growth 3Y0.27%
GM growth 5Y-1.34%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ZJYL is creating some value.
ZJYL has less shares outstanding than it did 1 year ago.
ZJYL has less shares outstanding than it did 5 years ago.
The debt/assets ratio for ZJYL is higher compared to a year ago.
2.2 Solvency
ZJYL has an Altman-Z score of 7.41. This indicates that ZJYL is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.41, ZJYL belongs to the best of the industry, outperforming 85.56% of the companies in the same industry.
ZJYL has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
ZJYL has a Debt to Equity ratio (0.37) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.41 |
ROIC/WACC0.69
WACC7.43%
2.3 Liquidity
A Current Ratio of 2.58 indicates that ZJYL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.58, ZJYL is in line with its industry, outperforming 46.52% of the companies in the same industry.
ZJYL has a Quick Ratio of 2.27. This indicates that ZJYL is financially healthy and has no problem in meeting its short term obligations.
ZJYL has a Quick ratio of 2.27. This is comparable to the rest of the industry: ZJYL outperforms 55.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.27 |
3. Growth
3.1 Past
ZJYL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.83%.
The Earnings Per Share has been growing by 14.87% on average over the past years. This is quite good.
ZJYL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -31.65%.
ZJYL shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.07% yearly.
EPS 1Y (TTM)-37.83%
EPS 3Y25.99%
EPS 5Y14.87%
EPS Q2Q%-12.17%
Revenue 1Y (TTM)-31.65%
Revenue growth 3Y6.97%
Revenue growth 5Y-1.07%
Sales Q2Q%2.96%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 43.00, ZJYL can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ZJYL is valued a bit cheaper than the industry average as 68.45% of the companies are valued more expensively.
ZJYL is valuated expensively when we compare the Price/Earnings ratio to 27.73, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ZJYL is valued a bit cheaper than 67.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 35.19 |
4.3 Compensation for Growth
ZJYL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)2.89
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ZJYL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JIN MEDICAL INTERNATIONAL LT
NASDAQ:ZJYL (12/20/2024, 8:00:02 PM)
After market: 0.8799 +0.02 (+2.31%)0.86
+0.01 (+1.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners1.14%
Inst Owner Change45.95%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap134.63M
AnalystsN/A
Price TargetN/A
Short Float %2.34%
Short Ratio2.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43 | ||
| Fwd PE | N/A | ||
| P/S | 6.69 | ||
| P/FCF | N/A | ||
| P/OCF | 326.07 | ||
| P/B | 5.13 | ||
| P/tB | 5.36 | ||
| EV/EBITDA | 35.19 |
EPS(TTM)0.02
EY2.33%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFY0.31%
SpS0.13
BVpS0.17
TBVpS0.16
PEG (NY)N/A
PEG (5Y)2.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.06% | ||
| ROE | 11.07% | ||
| ROCE | 8.83% | ||
| ROIC | 5.1% | ||
| ROICexc | 18.32% | ||
| ROICexgc | 20.63% | ||
| OM | 11.55% | ||
| PM (TTM) | 14.44% | ||
| GM | 34.73% | ||
| FCFM | N/A |
ROA(3y)11.23%
ROA(5y)12.44%
ROE(3y)16.18%
ROE(5y)20.61%
ROIC(3y)11.31%
ROIC(5y)14.68%
ROICexc(3y)21.85%
ROICexc(5y)23.41%
ROICexgc(3y)22.27%
ROICexgc(5y)23.85%
ROCE(3y)14.9%
ROCE(5y)21.53%
ROICexcg growth 3Y4.14%
ROICexcg growth 5Y-15.67%
ROICexc growth 3Y4.27%
ROICexc growth 5Y-15.45%
OM growth 3Y-0.18%
OM growth 5Y-6.48%
PM growth 3Y2.15%
PM growth 5Y-3.78%
GM growth 3Y0.27%
GM growth 5Y-1.34%
F-Score4
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.79 | ||
| Cap/Depr | 504.33% | ||
| Cap/Sales | 5.8% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 16.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.27 | ||
| Altman-Z | 7.41 |
F-Score4
WACC7.43%
ROIC/WACC0.69
Cap/Depr(3y)24.63%
Cap/Depr(5y)25.62%
Cap/Sales(3y)0.33%
Cap/Sales(5y)0.41%
Profit Quality(3y)127.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.83%
EPS 3Y25.99%
EPS 5Y14.87%
EPS Q2Q%-12.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-31.65%
Revenue growth 3Y6.97%
Revenue growth 5Y-1.07%
Sales Q2Q%2.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.41%
EBIT growth 3Y6.78%
EBIT growth 5Y-7.48%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-139.11%
FCF growth 3Y8.22%
FCF growth 5YN/A
OCF growth 1Y-79.02%
OCF growth 3Y7.46%
OCF growth 5YN/A